Pylera Shortage: What Providers and Prescribers Need to Know in 2026

Your patients who have been prescribed Pylera may be calling your office with a familiar complaint: they can't find it at their pharmacy. While Pylera (bismuth subcitrate potassium/metronidazole/tetracycline) does not appear on the FDA's official Drug Shortage Database, real-world pharmacy availability remains inconsistent, and cost-related access barriers are significant. This guide explains the current situation and offers actionable guidance for prescribers and care teams.

Current Status: Not a Formal Shortage, But Real Access Challenges Exist

Pylera is not listed on the FDA Drug Shortages Database or the ASHP Drug Shortages Database as of 2026. Manufacturer H2 Pharma has not reported a production or supply disruption. However, providers should be aware that the absence of a formal shortage listing does not mean uniform availability at the pharmacy level.

The primary drivers of access issues are:

Cost: Retail price of $300–$400 per 10-day course is prohibitive for uninsured or underinsured patients. Insurance coverage is fragmented, with many plans requiring prior authorization or not covering Pylera at all.

Pharmacy stocking decisions: Pylera is a niche, high-cost medication. Pharmacies with low fill volume for it may not maintain standing inventory. Smaller independent pharmacies are particularly unlikely to stock it.

Distribution variability: Narrower distribution compared to high-volume generic drugs creates regional gaps in availability.

2024 ACG Guideline Update: What Changed for Prescribers?

The 2024 American College of Gastroenterology (ACG) guideline update significantly revised H. pylori treatment recommendations, with implications for how prescribers think about Pylera and its alternatives:

Optimized bismuth quadruple therapy (BQT) is now the preferred first-line empiric treatment for treatment-naïve patients when antibiotic susceptibility is unknown — this is the regimen Pylera delivers in convenient capsule form

Clarithromycin triple therapy is no longer recommended empirically due to clarithromycin resistance rates exceeding 30% in U.S. isolates

Vonoprazan-based regimens and rifabutin triple therapy (Talicia) are recognized as empiric alternatives for treatment-naïve patients, particularly when BQT is unavailable or contraindicated

14-day BQT is the optimal duration — note that Pylera is prescribed as a 10-day course, which is the FDA-approved duration, though some data support 14-day treatment for higher eradication rates

Antibiotic Resistance Context in 2026

Understanding antibiotic resistance patterns is critical for H. pylori treatment selection. Current U.S. data show:

Clarithromycin resistance: approximately 32% of U.S. H. pylori isolates

Levofloxacin resistance: approximately 38% of U.S. H. pylori isolates

Metronidazole resistance: approximately 42% — but importantly, metronidazole resistance has less impact on bismuth quadruple therapy efficacy than on other regimens

Amoxicillin resistance: remains low at approximately 3%, making amoxicillin-containing regimens favorable where appropriate

Alternative Prescribing Options When Pylera Is Unavailable or Unaffordable

Prescribers have several effective options when Pylera is inaccessible:

Traditional bismuth quadruple therapy (separate generic components): Bismuth subsalicylate + metronidazole + tetracycline + PPI. All components are available generically at much lower cost. Standard 14-day course.

Talicia (rifabutin/omeprazole/amoxicillin): FDA-approved 2019. Excellent for metronidazole-resistant strains and salvage therapy. Requires amoxicillin tolerance. Very high cost.

Vonoprazan-based regimens (Voquezna Triple Pak or Dual Pak): FDA-approved 2022. Strong acid suppression. Triple Pak preferred when clarithromycin susceptibility is known or confirmed; Dual Pak for penicillin-tolerant patients without clarithromycin susceptibility data.

Patient Assistance and Savings Programs

For patients who need Pylera specifically, several cost-reduction options exist:

GoodRx and SingleCare discount cards can reduce out-of-pocket cost to approximately $187–$200 per course at participating pharmacies

Patient assistance programs are available for qualifying patients with household incomes below approximately $40,000 for individuals or $100,000 for larger families

Prior authorization support: if your practice has a care coordinator or prior auth team, submitting PA requests with documentation of medical necessity can sometimes unlock coverage

How to Help Your Patients Locate Pylera

Recommend medfinder to patients who are having trouble finding Pylera. medfinder contacts pharmacies in the patient's area to find which ones have the medication in stock. This eliminates hours of phone calls and frustration for patients already dealing with an uncomfortable GI infection.

Additionally, encourage patients to ask their pharmacy to special-order Pylera if it's not in stock — most pharmacies can source it within 24–48 hours through their drug distributor. Hospital outpatient pharmacies affiliated with your health system are also likely to have better inventory of specialty GI medications.